Early Access

10-KPeriod: FY2003

DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2003

Filed March 10, 2004For Securities:DHR

Summary

Danaher Corporation's 2003 10-K report highlights a year of significant growth, driven by both organic improvements and strategic acquisitions. The company's Process/Environmental Controls segment, which represents the majority of its revenue (77%), saw strong performance bolstered by its Environmental, Motion, Electronic Test, and Product Identification platforms. The Tools & Components segment also contributed, albeit with a smaller share (23%). Financially, Danaher demonstrated robust operating cash flow generation, increasing by approximately 21% over the prior year, and maintained a strong liquidity position with substantial cash reserves. The company actively pursued its growth strategy through acquisitions, investing significantly in businesses that complement its existing operations or establish new strategic platforms, particularly in the burgeoning medical technology sector. Looking ahead, Danaher expressed confidence in its ability to integrate these acquisitions and anticipates continued revenue growth, supported by its proprietary Danaher Business System (DBS) aimed at continuous performance improvement.

Key Highlights

  • 1Revenue increased by approximately 15.5% in 2003 compared to 2002, with acquisitions contributing about 10%, favorable currency translation around 4%, and existing businesses providing 1.5% growth.
  • 2The Process/Environmental Controls segment is the dominant revenue generator, accounting for 77% of total sales in 2003, driven by strategic platforms like Environmental and Motion.
  • 3The Tools & Components segment represents 23% of revenue, with the Mechanics' Hand Tools business being a key contributor.
  • 4Danaher generated substantial operating cash flow of $862 million in 2003, an increase of 21% from 2002.
  • 5The company made significant investments in acquisitions throughout 2003, totaling approximately $312 million, and further expanded its Medical Technology platform with substantial acquisitions of Radiometer A/S and the Gendex business shortly after year-end.
  • 6Danaher's commitment to innovation is reflected in its R&D expenditures, which increased to $207 million in 2003.
  • 7The company maintains a strong balance sheet with approximately $1.2 billion in cash and cash equivalents as of December 31, 2003.

Frequently Asked Questions